by he Center for Higher Studies of the Pharmaceutical Industry (CESIF)integral part of the Educational Group metrodoracelebrates his 30th anniversary consolidating itself as the leader in the highly specialized training in the pharmaceutical, biotechnology, food, chemical and cosmetic sectors. The center, which has offices in Barcelona and Madrid, commemorates this trajectory of educational commitment and close relationship with the industry with the launch, this February and March in Barcelona, of a new edition of three of its graduate programs most in demand in the Catalan capital.
These are the Master in Pharmaceutical and Parapharmaceutical Industry, the Master in Cosmetics and Dermopharmacy and the Master in Clinical Trial Monitoring and Medical Affairs.
hector martinezCEO of Metrodora, a group that trains more than 26,000 students a year and of which CESIF is a part, describes this school as “reference center” and highlights the high demands of its programs and the close relationship with the pharmaceutical world. “We have a tremendous link with the industry,” they explain.
Guaranteed internships and competitive salaries
One of the things that CESIF has taken care of over these years is practical training: more than 11,000 students have completed specialized internships and all of them have been with average salaries of 1,300 euros for a year. Martínez explains that this is a sector “very premium” in every sense and that the courses they offer “include all those necessary means to be able to respond to what the industry demands.”
“It is a leading companyvery connected to reality, with teachers who are managers of the pharmaceutical industry, who bring novelty, updating, in a very practical training, where we work on skills, languages and the professional development of the student to guarantee a better entry into the market. work”, he assures. With more than 1,000 internships a year, the objective of the center’s management is to establish stability in the students and guarantee good personal and professional development.
High employability
This long-term training model, beyond conventional university training, is one of the group’s keys. Currently, the center has 800 job offers a yearguaranteeing a 90% employability to their students once they finish their studies. This extensive job bank is possible thanks to agreements with more than 400 companies in the sector. The profile of these collaborating companies ranges from ‘start-ups’ to national and multinational companies.
Direct connection with the industry.
And one of the priorities is to ensure its students a direct connection with the pharmaceutical industry and with business reality through a faculty made up of active professionals and organized visits to companies in the sector. This immersive experience guarantees students that, added to the internships, they can access the world of work in the best conditions.
“CESIF already has more than 12,000 graduates who are managers or professors and who have made a career in the pharmaceutical industry, participating in a beautiful virtuous circle,” Martínez emphasizes. “Any industry in the sector that you ask will tell you that either they have hired CESIF personnel, or their managers are teachers here,” he boasts. “When they demand industry professionals, they directly search our job board.“, he emphasizes.
Internationalization in the future
he 90% of CESIF students are local, but now, in a general framework of internationalization, the center wants to focus on attracting international students, expanding spaces and diversifying the offer.
“We want to have more international students. We will do this by promoting online training and focusing especially on the latin american marketwhere There is no offer of specialized pharmaceutical training despite having a great demand,” he stated. In addition, they will also enhance the national growthstrengthening the link between its headquarters Madrid and Barcelona.
In the Catalan capital, new editions of three renowned programs related to the pharmaceutical and parapharmaceutical, cosmetics and dermopharmacy industries and to the monitoring of clinical trials will be launched during the month of February and March.
